Kidney Week

Abstract: SA-PO0216

Cancer Treatment-Associated Hypomagnesemia: Analysis from a Large Pharmacovigilance Database

Session Information

• Onconephrology: MGRS, HSCT, Electrolytes, RCC, and More
  November 08, 2025 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Onconephrology

• 1700 Onconephrology

Authors

• Klomjit, Nattawat, Division of Nephrology and Hypertension, Department of Medicine, University of Minnesota, Minneapolis, Massachusetts, United States

Nattawat Klomjit, MD, FASN

• Evans, Rich, University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

Rich Evans, PhD

• Pirovano, Marta, Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Marta Pirovano, MD

• Ortega, Jessica L., Division of Renal Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States

Jessica L. Ortega

• Alikhan, Firasat Mir, Division of Renal Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States

Firasat Mir Alikhan

• Chewcharat, Api, Division of Renal Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, United States

Api Chewcharat, MD, MPH

• Chowdhury, Raad Bin Zakir, Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Raad Bin Zakir Chowdhury, MD, FASN

• Sise, Meghan E., Division of Nephrology, Department of Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States

Meghan E. Sise, MD, MS

• Jhaveri, Kenar D., Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine, Boston, Massachusetts, United States

Kenar D. Jhaveri, MD, FASN

• Gupta, Shruti, Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Shruti Gupta, MD, MPH

Background

Hypomagnesemia is common in patients with cancer; however, there is a lack of real-world data on its frequency in the setting of older and newer antineoplastic agents.

Methods

We utilized VigiBase to examine the frequency of hypomagnesemia after treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (anti-EGFR mABs), anti-EGFR tyrosine kinase inhibitors (anti-EGFR TKIs), anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibodies (anti-HER2 mABs), and conventional chemotherapy. The strength of association was determined using information component (IC), a measure of disproportionality between observed and expected number of reports for a drug-event combination. A positive IC₀₂₅ indicates that the number of observed reports exceeded the expected reports.

Results

Between 2010-2024, there were 18,388 reports of antineoplastic-associated hypomagnesemia in 2226 individuals. The drugs with the highest IC025 were panitumumab (6.22), cetuximab (4.85), and cisplatin (3.26) (Figure). Hypomagnesemia was reported most commonly after conventional chemotherapy (n=896, 48.6%) and anti-EGFR mABs (n=769, 41.7%). Time to hypomagnesemia was shortest following conventional chemotherapy (18.3 days, IQR 7-50) and longest in those receiving anti-EGFR mABs (77.5 days, IQR 28-182.1). Gastrointestinal and hepatobiliary cancers (40.1%) were the most common types of cancer, followed by lung (14.1%), and head and neck cancer (13.4%).Time to onset of hypomagnesemia was the shortest in those in the lowest age group (≤17 years).

Conclusion

Hypomagnesemia was most frequent with conventional chemotherapy and anti-EGFR mABs; thus, patients treated with these agents should be monitored for hypomagnesemia, and may benefit from preventative or therapeutic strategies.

Funding

• NIDDK Support

Digital Object Identifier (DOI)

• doi: 10.1681/ASN.2025drmbhkcq